Who Supplies Sitagliptin to India from GREECE

To import finished pharmaceutical formulations containing Sitagliptin into India, the Central Drugs Standard Control Organization (CDSCO) mandates that both import registration and an import license be obtained as per the Drugs and Cosmetics Act and associated rules. This requirement ensures that imported drugs meet the necessary quality, safety, and efficacy standards. The registration process involves submitting detailed product information, including manufacturing details, clinical data, and labeling information. The import license is issued upon successful registration and compliance with all regulatory requirements. The timeline for obtaining these approvals can vary but typically ranges from several months to a year, depending on the complexity of the product and the completeness of the submitted documentation. For Sitagliptin formulations under HS Code 30049099, specific requirements include providing a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificates, and stability data demonstrating the product's shelf-life under Indian conditions. Additionally, a No Objection Certificate (NOC) from the manufacturer may be required to confirm that the product is not under patent protection in India.

Imported Sitagliptin formulations must undergo quality testing at CDSCO-approved laboratories to ensure compliance with Indian Pharmacopoeia standards. Each batch requires a Certificate of Analysis (CoA) confirming that the product meets all specified quality parameters. Stability studies must be conducted in accordance with International Council for Harmonisation (ICH) guidelines, specifically for Zone IV conditions, to assess the product's stability in India's climate. Upon arrival, customs drug inspectors perform port inspections to verify the authenticity of the product and ensure that it matches the submitted documentation. If a batch fails to meet the required standards, it may be rejected, leading to potential delays and additional costs for the importer.

In April 2025, the CDSCO introduced new regulations requiring import registration and licenses for all imported medicines, including finished pharmaceutical formulations containing Sitagliptin. This policy aims to prevent the sale of unapproved or illegal medicines in the Indian market. The implementation of the Production Linked Incentive (PLI) scheme has also impacted the import of finished formulations, encouraging domestic manufacturing and reducing dependency on imports. While the PLI scheme primarily targets domestic production, it indirectly affects import policies by promoting self-reliance in pharmaceutical manufacturing. Bilateral agreements between India and Greece have facilitated smoother trade relations, but no specific exemptions or preferential treatment have been established for Greek-origin pharmaceutical imports.

India imports finished Sitagliptin formulations to meet the demand for patented and branded products not yet available domestically. Specific dosage forms, such as combination therapies or extended-release formulations, may not be produced locally, necessitating imports. Despite a robust domestic pharmaceutical industry, certain specialized formulations are still sourced from abroad to cater to diverse patient needs. The market size for Sitagliptin formulations in India is substantial, with imports contributing to a significant portion of the total market value.

The Basic Customs Duty (BCD) for Sitagliptin formulations under HS Code 30049099 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is applied, resulting in a total duty of 20%. The Goods and Services Tax (GST) at 12% is levied on the import value, including the duty. Therefore, the total landed cost for importing Sitagliptin formulations into India is calculated as follows:

| Component | Percentage | Calculation Method | |-------------------------|------------|-----------------------------------------------| | Basic Customs Duty | 10% | 10% of CIF value | | Social Welfare Surcharge| 10% | 10% of CIF value | | GST | 12% | 12% of (CIF value + Basic Duty + SWS) | | Total Landed Cost | 20% + 12% | Sum of above components |

This structure ensures that the total duty and taxes amount to 32% of the CIF value.

India sources Sitagliptin formulations from Greece due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized dosage forms not produced domestically. Greek manufacturers offer high-quality products that meet the stringent requirements of the Indian market. While other countries like China, Germany, and the United States also supply Sitagliptin formulations, Greece's competitive advantage lies in its consistent product quality, reliable supply chain, and compliance with international regulatory standards. Greece's share in India's Sitagliptin import market is modest but significant, reflecting its role as a trusted supplier.

India imports Sitagliptin formulations from Greece due to the availability of specialized dosage forms and high-quality products that are not yet produced domestically. Greek manufacturers offer patented formulations and advanced technologies that cater to specific patient needs, filling gaps in the Indian market. The strategic sourcing from Greece allows Indian buyers to offer a diverse range of Sitagliptin formulations, enhancing their product portfolios and meeting the demands of the diabetic population.

When compared to other origins such as China, Germany, and the United States, Greece offers a competitive advantage in terms of product quality, regulatory compliance, and reliability. While China may offer lower prices, concerns regarding quality and regulatory standards can be a deterrent. Germany and the United States provide high-quality products but at higher costs. Greece strikes a balance between quality and cost, making it an attractive sourcing option for Indian importers.

Potential risks for Indian importers include currency fluctuations, regulatory changes, and shipping disruptions. While Greece has a stable political and economic environment, any changes in trade policies or regulations can impact the supply chain.